期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

第二代酪氨酸激酶抑制剂,慢性髓性白血病的一线选择？ 被引量：2

Second-generation tyrosine kinase inhibitors： the first-line treatment strategy of chronic myeloid leukemia patients？
原文传递
导出
摘要 15年前,第一代酪氨酸激酶抑制剂（TKI）伊马替尼的问世,使慢性髓性白血病（CML）患者通过减少疾病进展显著延长了生存期,对于绝大多数患者而言,CML已不再是威胁生命的不治之症.IRIS研究显示,初发CML慢性期（CP）患者接受伊马替尼治疗,8年无事件生存（EFS）、无疾病进展生存（PFS）和总生存（OS）率分别为81%、92%和85%[1].
作者 江倩
机构地区 北京大学人民医院、北京大学血液病研究所
出处 《中华血液学杂志》 CAS CSCD 北大核心 2014年第12期1049-1052,共4页 Chinese Journal of Hematology
基金 北京市科学技术委员会基金（z131100004013026）
关键词 酪氨酸激酶抑制剂 慢性髓性白血病 第二代 伊马替尼 疾病进展 显著延长 不治之症 CML
分类号 R733.72 [医药卫生—肿瘤]
  • 相关文献

参考文献18

  • 1Deininger M, O' Brien SG, Guilhot E et al. IRIS 8-year follow up: Sustained survival and low risk for progression of events in patients with newly diagnosed CML treated with imatinib [J]. Blood(ASH Annual Meeting), 2009, 114:Abstract1126.
  • 2Jiang Q, Xu LP, Liu DH, et al. Imatinib results in better out- comes than HLA-identical sibling transplants in young persons with newly diagnosed chronic-phase chronic myelogenous leu- kemia[ J]. Leukemia, 2013, 27(12) :2410-2413,.
  • 3Druker B, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia [J]. N Engl J Med, 2006, 355(23):2408-2417.
  • 4de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis [J]. J Clin Oncol, 2008, 26(20): 3358-3363.
  • 5Cortes JE, Hochhaus A, Kim DW, et al. Four-year (Yr) follow- up of patients (Pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) receiving dasatinib or imatinib: efficacy based on early response [J]. Blood (ASH Annual Meeting), 2013, 122: Abstract 653.
  • 6Larson RA, Kim DW, Jootar S, et al. ENESTnd 5-year (y) update: Long-term outcomes of patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with frontline nilotinib (NIL) versus imatinib (IM) [J]. J Clin Oncol (50th ASCO Annual Meeting), 2014, Suppl: Abstract 7073.
  • 7Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION) [J]. Blood, 2014, 123(4):494-500.
  • 8Rea D, Mirault T, Raffoux E, et al. Identification of patients (pts) with chronic myeloid leukemia (CML) at high risk of artery occlusive events (AOE) during treatment with the 2rid generation tyrosine kinase inhibitor (TKI) nilotinib, using risk Stratification for cardiovascular diseases (CVD) [J]. Blood (ASH Annual Meeting), 2013, 122: Abstract 2726.
  • 9Rea D, Gautier JF, Massimo B, et al. Incidence of hyperglyce- mia by 3 years in patients (Pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib (NIL) or imatinib (IM) in ENESTnd [ J ]. Blood ( ASH Annual Meeting), 2012, 120: Abstract 1686.
  • 10Rea D, Mirault T, Gautier JF, et al. Prospective analysis of plasma cholesterol and triglycerides in patients (pts) with chronic phase (CP)-chronic myeloid leukemia (CML) duringtreatment with the 2ndgeneration tyrosine kinase inhibitor (TKI) nilotinib [J]. Blood(ASH Annual Meeting), 2013, 122: Abstract 4042.

同被引文献9

引证文献2

二级引证文献2

中华血液学杂志
2014年 第12期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部